Bupivacaine (Marcaine)

Bupivacaine, commonly known by the brand name Marcaine, is a long-acting amide local anesthetic used in veterinary medicine to provide regional anesthesia and extended pain control in various species including rabbits. This medication belongs to the same chemical class as lidocaine but offers the significant advantage of substantially longer duration of action, making it particularly valuable for procedures where extended post-operative analgesia is desirable. In rabbit medicine, bupivacaine has become an important component of multimodal pain management protocols, helping to reduce reliance on systemic analgesics while providing excellent localized pain control.

The mechanism of action of bupivacaine involves reversible blockade of sodium channels in nerve membranes, which prevents the generation and conduction of nerve impulses. When applied to sensory nerves, this blockade eliminates the transmission of pain signals from the affected area to the central nervous system. The drug also blocks motor nerve conduction when applied to mixed nerves, potentially causing temporary paralysis of muscles in the affected region. Bupivacaine's high lipid solubility and strong protein binding contribute to its prolonged duration of action compared to other local anesthetics, with effects typically lasting four to eight hours or longer depending on the technique used and location of administration.

Bupivacaine is available in various concentrations as an injectable solution, with or without added epinephrine. The epinephrine-containing formulations cause local vasoconstriction that reduces systemic absorption and prolongs local anesthetic effect, though these formulations are typically avoided in areas with end-arterial blood supply. In rabbit patients, veterinarians select the appropriate concentration and formulation based on the specific application, patient size, and total dose limitations. The solution is administered through various techniques including local wound infiltration, peripheral nerve blocks, dental blocks, and epidural injection, each requiring proper anatomical knowledge and technical skill.

The use of bupivacaine in rabbits contributes to improved patient welfare by providing effective analgesia that reduces stress and facilitates recovery from surgical procedures. Adequate pain control is particularly important in rabbits because pain and stress can trigger dangerous complications including gastrointestinal stasis, immunosuppression, and behavioral changes that affect eating and normal activities. By incorporating local anesthetic techniques with bupivacaine into anesthetic and analgesic protocols, rabbit-savvy veterinarians can provide more complete pain management while potentially reducing doses of systemic medications that may carry their own risks. All use of bupivacaine in rabbits should be under the direct supervision of a veterinarian experienced in exotic animal medicine and regional anesthesia techniques.

The primary indication for bupivacaine in rabbit medicine is the provision of local anesthesia and analgesia for surgical procedures and painful conditions requiring extended pain relief. As a long-acting local anesthetic, bupivacaine excels in situations where sustained pain control is needed without repeated medication administration. Surgical site infiltration at the time of wound closure provides hours of post-operative analgesia that smooths recovery and reduces the total amount of systemic pain medication required. This application proves valuable in procedures ranging from simple mass removals to more extensive abdominal or orthopedic surgeries.

Dental procedures represent an important area of application for bupivacaine in rabbit patients, as dental disease constitutes one of the most common health problems in domestic rabbits. Dental nerve blocks using bupivacaine can provide profound anesthesia for extractions, abscess drainage, and other oral procedures while extending analgesia into the post-operative period. The mandibular and infraorbital nerve blocks commonly performed in rabbits require anatomical knowledge specific to lagomorph skull structure, and proper technique ensures effective blockade while avoiding complications. Extended analgesia from bupivacaine helps rabbits return to eating sooner after dental procedures.

Regional nerve blocks for limb procedures showcase bupivacaine's utility in rabbit orthopedic and soft tissue surgery. Sciatic and femoral nerve blocks provide anesthesia and analgesia for hindlimb procedures, while brachial plexus or specific peripheral nerve blocks address forelimb needs. These regional techniques can dramatically reduce general anesthetic requirements and provide superior post-operative pain control compared to systemic analgesics alone. In rabbits undergoing limb amputation, fracture repair, or other painful orthopedic procedures, properly performed nerve blocks with bupivacaine contribute significantly to patient comfort during recovery.

Epidural anesthesia using bupivacaine provides analgesia for procedures involving the caudal body including pelvic surgeries, tail amputations, perineal procedures, and some abdominal surgeries. The epidural route delivers local anesthetic around spinal nerves, blocking sensation from the regions they supply. This technique requires specialized training and careful attention to dose calculations to avoid excessive cranial spread of blockade that could affect respiratory function. In appropriate cases, epidural analgesia offers excellent pain control with minimal systemic effects, making it particularly valuable in patients where high doses of systemic analgesics might be problematic.

Wound infiltration for chronic pain management or tumor-related discomfort represents an additional application where bupivacaine's extended duration proves beneficial. While not a substitute for definitive treatment, local anesthetic infiltration can provide temporary relief for rabbits with painful conditions while diagnostic evaluation or treatment planning proceeds. The technique may also supplement other analgesic approaches in patients with pain that responds incompletely to systemic medications. As with all uses, careful attention to maximum safe doses and proper technique ensures that bupivacaine provides benefit without excessive risk.

Dosing of bupivacaine in rabbits requires careful calculation by a veterinarian experienced in local anesthetic use in exotic species, as the margin between therapeutic and toxic doses is narrower than for many other medications. The fundamental principle governing bupivacaine dosing is that total body dose must remain below toxic thresholds regardless of the route or site of administration. Maximum recommended doses in rabbits typically range from one to two milligrams per kilogram body weight, though conservative practice favors staying at the lower end of this range. The concentration of solution selected directly affects the volume that can be safely administered, with lower concentrations allowing larger volumes for widespread infiltration while higher concentrations minimize tissue distortion in confined spaces.

The administration technique varies based on the intended application and anatomical target. Local wound infiltration involves depositing small amounts of bupivacaine solution throughout the tissues that will be incised or have been incised during surgery. This technique requires systematic distribution of the drug to ensure complete coverage of the surgical site while tracking the total dose administered. For wound infiltration, lower concentrations such as 0.25 percent bupivacaine allow adequate volume for thorough tissue saturation while limiting total dose. The infiltration should be performed with attention to tissue planes and structures likely to transmit painful stimuli.

Peripheral nerve blocks require identification of specific anatomical landmarks to guide needle placement near target nerves. The goal is to deposit local anesthetic solution in close proximity to the nerve without direct nerve injection, which could cause damage. For major nerve blocks such as sciatic or brachial plexus blocks, volumes of 0.1 to 0.3 milliliters per site using 0.5 percent bupivacaine typically provide adequate effect, though exact volumes depend on rabbit size and specific block technique. Nerve stimulator guidance or ultrasound-assisted techniques, when available, can improve block success rates and reduce the volume required. Onset of nerve blocks typically occurs within fifteen to thirty minutes, with duration extending four to eight hours or longer.

Dental nerve blocks in rabbits target specific nerves supplying the dental structures, primarily the mandibular nerve for lower jaw procedures and the infraorbital nerve for upper jaw work. Small volumes of 0.5 percent bupivacaine, typically 0.1 to 0.2 milliliters per site, suffice for these blocks given the small target nerve size in rabbits. Proper needle placement requires understanding of rabbit skull anatomy, which differs significantly from that of dogs and cats. Successful dental blocks provide complete anesthesia to the targeted teeth and surrounding tissues, allowing painless dental work and extended post-procedural comfort.

Epidural administration follows strict protocols regarding technique and dosing to ensure safety and efficacy. The lumbosacral space is typically accessed with the rabbit in lateral or sternal recumbency, and proper placement is confirmed before injecting. Epidural doses are calculated carefully to achieve the desired level of blockade without excessive cranial spread that could affect respiratory function. The addition of preservative-free opioids to epidural bupivacaine can enhance and extend analgesia, though such combinations require additional expertise and monitoring.

Onset time for bupivacaine varies by administration technique, with infiltration providing relatively rapid effect while nerve blocks and epidural administration may require fifteen to thirty minutes for full development. Veterinary teams should account for this onset time when planning procedures and should verify block effectiveness before proceeding. Duration of effect depends on multiple factors including dose, concentration, site of administration, and individual patient variation, but generally ranges from four to eight hours for most applications. Additional systemic analgesia should be planned to maintain comfort as the block resolves.

Bupivacaine is generally well tolerated by rabbit patients when administered properly at appropriate doses, with the majority of treated animals experiencing effective analgesia without significant adverse effects. However, like all local anesthetics, bupivacaine carries the potential for both local and systemic side effects that veterinary teams must recognize and be prepared to manage. Understanding the potential adverse effects allows for appropriate patient monitoring and prompt intervention if complications occur.

Local tissue reactions at injection sites represent the most common adverse effects of bupivacaine administration. Mild swelling, redness, and tenderness at infiltration sites typically resolve without treatment within twenty-four to forty-eight hours. More significant tissue irritation can occasionally occur, particularly with higher concentrations or repeated injections in the same area. Proper injection technique minimizing tissue trauma and avoiding excessive volumes in any single location helps reduce local reactions. Tissue necrosis, while rare, can result from injection into tissues with compromised blood supply or from excessive local concentrations.

Systemic toxicity represents the most serious potential adverse effect of bupivacaine and results from excessive blood concentrations of the drug. Toxicity can occur from absolute overdose, inadvertent intravascular injection, or rapid absorption from highly vascular injection sites. Early signs of systemic toxicity include restlessness, tremors, and disorientation, progressing to seizures in more severe cases. Cardiovascular toxicity manifests as arrhythmias, hypotension, and potentially cardiac arrest. Bupivacaine is notable among local anesthetics for its particular cardiotoxicity, making prevention of systemic toxicity especially important with this agent. Adherence to maximum dose recommendations and careful aspiration before injection to avoid intravascular administration are essential safety measures.

Neurological effects from regional nerve blocks can include prolonged sensory or motor deficits beyond the expected duration of action. While temporary nerve dysfunction from local anesthetic block is expected and desirable, persistent deficits lasting beyond twenty-four hours may indicate nerve injury from the injection itself or from neurotoxic effects of the drug. Proper technique avoiding direct intraneural injection and use of appropriate needle sizes minimize this risk. Patients exhibiting persistent neurological deficits require veterinary evaluation and monitoring for recovery.

Motor blockade affecting mobility represents a predictable effect of nerve blocks and epidural administration rather than a true adverse effect, but requires management to prevent secondary complications. Rabbits with motor block to the hindquarters may be unable to urinate normally and may require bladder expression or catheterization. They also require appropriate bedding and housing to prevent injury during the period of impaired mobility. The temporary nature of this effect should be explained to owners when relevant, along with expected timeline for return of normal function.

Gastrointestinal effects are not direct results of bupivacaine administration but deserve consideration in rabbit patients undergoing any procedure. The stress of handling, underlying conditions requiring treatment, and effects of concurrent medications can all contribute to gastrointestinal dysfunction. Maintaining normal eating behavior and monitoring fecal output remain important aspects of post-procedural care regardless of the specific anesthetic or analgesic agents used. Rabbits that fail to resume eating within several hours of recovering from procedures should receive prompt veterinary attention.

Bupivacaine is contraindicated in rabbits with known hypersensitivity to bupivacaine or other amide local anesthetics including lidocaine, mepivacaine, and prilocaine. Cross-reactivity among amide local anesthetics is common, and patients with documented allergic reactions to one agent in this class should generally avoid others. True allergic reactions to local anesthetics are relatively uncommon but can manifest as local swelling, urticaria, or more serious systemic responses. Any history of unusual reactions to local anesthetics should prompt careful evaluation and consideration of alternative analgesic approaches.

Injection into infected or severely inflamed tissue represents a relative contraindication to bupivacaine use. Local infection reduces the effectiveness of local anesthetics due to altered tissue pH that affects drug ionization and penetration, meaning expected analgesia may not be achieved. Additionally, injection into infected tissue risks spreading infection along needle tracks. When local anesthesia is required in the presence of infection, injection around rather than directly into the affected area may provide some benefit while reducing risks.

Epinephrine-containing bupivacaine formulations are contraindicated for use in areas with end-arterial blood supply, as the vasoconstriction produced by epinephrine can cause tissue ischemia and necrosis in regions lacking collateral circulation. In rabbits, this consideration applies to the ears, digits, and other extremities. Plain bupivacaine without epinephrine should be selected for procedures in these areas. The routine use of epinephrine-containing formulations is generally unnecessary in rabbit patients, as the extended duration of bupivacaine typically provides adequate analgesia without the additional vasoconstrictor effect.

Patients with severe cardiovascular disease require cautious consideration before bupivacaine administration due to the drug's potential for cardiotoxicity. While properly administered local or regional anesthesia at appropriate doses rarely produces significant cardiovascular effects, the margin for error narrows in patients with compromised cardiac function. Alternative local anesthetics with lower cardiotoxicity profiles, such as lidocaine for shorter procedures, may be preferred in patients with known heart disease. When bupivacaine is deemed necessary in cardiac patients, conservative dosing and enhanced monitoring are appropriate precautions.

Spinal or epidural administration of bupivacaine is contraindicated in patients with uncorrected hypovolemia, coagulation disorders, or local infection at the injection site. These conditions increase risks of complications including hypotension, epidural hematoma formation, and infection of the epidural space. Patients with neurological disease affecting the spine or with spinal deformities may also be poor candidates for epidural techniques. Thorough patient evaluation before epidural administration helps identify contraindications and allows appropriate case selection.

Pregnant rabbits near parturition require special consideration, as bupivacaine crosses the placenta and can affect neonates. While local anesthesia during pregnancy can generally be performed safely with attention to dose limits, epidural administration in late pregnancy may affect maternal pushing ability during delivery and can result in neonatal depression. The decision to use bupivacaine in pregnant patients should weigh the specific circumstances and available alternatives.

Drug interactions involving bupivacaine in rabbit patients primarily concern other medications affecting cardiovascular function, central nervous system activity, or local anesthetic metabolism. Thorough medication history review before bupivacaine administration helps identify potential interactions and allows appropriate protocol adjustments. While significant interactions are relatively uncommon with properly administered local anesthesia, awareness of potential issues contributes to patient safety.

Other local anesthetics administered concurrently with bupivacaine have additive toxic potential, requiring that total local anesthetic dose from all sources be considered when calculating safe limits. This consideration applies when different local anesthetics are used for different purposes during the same procedure, such as lidocaine for initial rapid-onset anesthesia followed by bupivacaine for extended duration. The toxicity of different local anesthetics is not simply additive but should be treated as approximately so for safety calculations. Veterinary teams should track total local anesthetic administration across all routes and agents.

Central nervous system depressants including sedatives, anesthetics, and opioids may have enhanced effects in the presence of significant systemic local anesthetic absorption. While this interaction rarely proves clinically significant with properly administered regional anesthesia, it becomes relevant if local anesthetic toxicity develops, as the combination of CNS-depressant drugs may worsen neurological symptoms. Patients receiving general anesthesia along with regional techniques should be monitored appropriately for the combined effects of all administered agents.

Antiarrhythmic medications, particularly those in the same class as local anesthetics such as Class IB antiarrhythmics, may interact with bupivacaine to increase risk of cardiac conduction abnormalities. Patients receiving chronic antiarrhythmic therapy require careful evaluation before bupivacaine administration, and consultation with a veterinary cardiologist may be appropriate for complex cases. Dose reductions and enhanced cardiac monitoring may be warranted when such combinations are unavoidable.

Medications affecting hepatic metabolism may theoretically influence bupivacaine clearance, as the drug undergoes extensive hepatic metabolism. Drugs that inhibit cytochrome P450 enzymes could potentially prolong bupivacaine effects and increase toxicity risk, though clinical significance of such interactions in rabbits receiving single local anesthetic doses is likely minimal. Patients with hepatic dysfunction from any cause may have reduced bupivacaine clearance warranting dose adjustment.

Vasoactive medications can influence local anesthetic distribution and duration by altering local blood flow at injection sites. Systemic vasoconstrictors may prolong local anesthetic effect similarly to locally administered epinephrine, while vasodilators could accelerate systemic absorption. These interactions are generally minor but may warrant consideration in patients receiving vasoactive medications for cardiovascular support or other indications. The interaction works in both directions, as local anesthetics themselves can influence vascular tone.

The use of bupivacaine in rabbits requires adherence to safety precautions designed to prevent complications, particularly the potentially serious consequences of systemic toxicity. All personnel administering bupivacaine should be trained in proper technique and aware of maximum safe doses for rabbit patients. Emergency equipment and medications for treating local anesthetic toxicity should be readily available whenever bupivacaine is used, including airway management supplies, oxygen, anticonvulsants, and cardiovascular support drugs.

Accurate patient weighing in appropriate units forms the foundation of safe dose calculation for bupivacaine administration. In small rabbit breeds, weighing in grams rather than kilograms reduces calculation errors that could result in overdose. The veterinarian should calculate maximum safe total dose before beginning administration and should communicate this limit to all team members assisting with the procedure. Running totals of administered drug should be maintained during procedures requiring multiple injection sites to ensure total dose remains within safe limits.

Aspiration before injection at each site helps avoid inadvertent intravascular administration, which could rapidly produce toxic blood concentrations. While negative aspiration does not guarantee extravascular placement, positive aspiration of blood clearly indicates the need to reposition before injecting. Slow injection with frequent aspiration allows early detection of intravascular migration that might occur during the injection process. These technical precautions are especially important for blocks performed near major blood vessels.

Monitoring during and after bupivacaine administration should include observation for signs of systemic toxicity, which may include restlessness, tremors, seizures, or cardiovascular abnormalities. Early recognition of toxicity allows prompt intervention before progression to more serious complications. Treatment of mild toxicity involves supportive care and allowing time for drug redistribution and metabolism, while severe toxicity with seizures or cardiovascular collapse requires aggressive intervention including seizure control, airway management, and cardiovascular support.

Patients with motor block from nerve blocks or epidural administration require appropriate nursing care to prevent complications from impaired mobility. Housing should prevent injury from falls or dragging of affected limbs. Urinary function should be monitored and supported as needed, as urinary retention can result from pelvic nerve blocks. The temporary nature of motor effects should be understood by all caregivers, and patients should be allowed to recover in a quiet, protected environment.

Special populations requiring additional caution include very young rabbits with immature hepatic function, geriatric rabbits with potential organ function decline, and rabbits with concurrent diseases affecting drug metabolism or cardiovascular function. Conservative dosing approaching the lower end of recommended ranges is prudent in these patients. Rabbits with hepatic disease may have prolonged drug clearance increasing toxicity risk, while cardiac patients may be more susceptible to the cardiovascular effects of any systemic absorption that occurs.

Bupivacaine injection solutions should be stored at controlled room temperature between 20 and 25 degrees Celsius, with brief excursions permitted in the range of 15 to 30 degrees Celsius according to standard pharmaceutical storage conventions. Protection from light is recommended for long-term storage, and solutions should be kept in their original packaging until time of use. Freezing should be avoided as it may affect solution stability and sterility. Multi-dose vials should have their contents dated when first punctured and discarded according to manufacturer recommendations or institutional protocols, typically within 28 days of opening.

Sterility must be maintained throughout the handling and administration process to prevent introduction of contaminants that could cause infection at injection sites. Aseptic technique should be used when withdrawing solution from vials, including proper disinfection of vial stoppers before needle insertion and use of sterile needles and syringes. Multi-dose vials should not be used if there is any indication of contamination, damage to the stopper, or visible particulate matter in the solution. Single-use vials eliminate some concerns about contamination during repeated access.

Visual inspection of bupivacaine solutions before use should confirm that the solution is clear and colorless without particulate matter, precipitates, or discoloration. Any solution that appears abnormal should be discarded rather than used. Solutions that have been frozen and thawed may show changes in appearance indicating compromised stability and should not be administered. Proper lighting during inspection helps detect subtle abnormalities that might otherwise be missed.

Handling bupivacaine requires standard precautions appropriate for pharmaceutical agents with systemic activity. While skin contact with solutions is unlikely to produce significant effects, handlers should avoid repeated or prolonged exposure and should wash any skin contact areas with soap and water. Accidental needlestick injuries involving bupivacaine warrant medical evaluation, particularly if the needle had been used in a patient or contaminated with blood. Spills should be cleaned promptly following standard pharmaceutical spill procedures.

Disposal of unused bupivacaine and empty containers should follow institutional policies for pharmaceutical waste and any applicable regulations. While bupivacaine is not a controlled substance, it remains a prescription medication that should not enter general waste streams. Sharp containers should be used for needles and syringes used in bupivacaine administration. Environmental considerations support proper disposal practices that prevent pharmaceutical contamination of water supplies and ecosystems.

Breed variations in response to bupivacaine relate primarily to size differences among domestic rabbit breeds, as the drug's effects and toxicity thresholds are fundamentally dose-dependent on a per-kilogram basis. The substantial size range among rabbit breeds, from dwarf varieties weighing under two kilograms to giant breeds exceeding ten kilograms, creates practical considerations for dose calculation and administration that must be addressed on an individual patient basis rather than by breed-specific protocols.

Dwarf rabbit breeds including Netherland Dwarfs, Holland Lops, Mini Rex, and similar small varieties present particular challenges for safe bupivacaine dosing due to their low body weights. The absolute maximum safe dose in these small patients is correspondingly small, leaving less margin for error. Precise patient weighing in grams and careful volume measurement become critical for safety in dwarf breed patients. Lower concentration solutions may be advantageous to allow adequate volume for effective blocks while staying within dose limits, though this must be balanced against the need for sufficient drug concentration for effective anesthesia.

Giant rabbit breeds such as Flemish Giants, Continental Giants, and Checkered Giants have larger absolute dose limits but should still receive careful dose calculation based on actual body weight. The proportionately larger anatomy of giant breeds may require modified techniques for nerve blocks and infiltration, as anatomical landmarks and depth of target structures differ from those in smaller rabbits. Larger volumes may be needed for effective wound infiltration in extensive surgical sites, but the same maximum dose per kilogram limits apply regardless of patient size.

Lop-eared rabbit breeds do not have known specific sensitivities to bupivacaine, but their unique ear anatomy warrants mention for procedures involving the head. The pendulous ears of lop breeds may affect positioning for dental blocks and should be carefully protected during any procedure involving the head. Infraorbital and mandibular nerve block techniques do not differ substantially between lop and upright-eared breeds, though anatomical variation requires adaptation of technique to individual patients.

Rex and Mini Rex breeds have distinctive coat characteristics but no known differences in local anesthetic response. Similarly, Angora and other wool breeds have no documented breed-specific bupivacaine considerations beyond the practical matter of managing dense coat for injection site preparation. Proper clipping and skin preparation ensure appropriate sterility regardless of coat type. Jersey Woolies and American Fuzzy Lops share these coat management considerations.

Age-related considerations transcend breed categories and significantly impact bupivacaine use decisions. Pediatric rabbits have developing hepatic enzyme systems that may affect drug metabolism, warranting conservative dosing in young animals. Geriatric rabbits may have age-related decline in hepatic and renal function affecting drug clearance, and may be more likely to have concurrent conditions affecting anesthetic and analgesic choices. Individual patient assessment remains more important than breed generalizations for optimizing bupivacaine use in any rabbit patient.

Other local anesthetics used in rabbit medicine offer alternatives to bupivacaine with different duration profiles and characteristics that may suit particular clinical situations. Lidocaine provides faster onset but shorter duration of action compared to bupivacaine, making it useful for brief procedures or diagnostic nerve blocks where extended duration is unnecessary. The combination of lidocaine for rapid onset with bupivacaine for extended duration represents a common approach that optimizes the beneficial characteristics of each drug, though total local anesthetic dose must be calculated considering both agents.

Mepivacaine offers intermediate duration between lidocaine and bupivacaine with relatively rapid onset, providing another option for procedures where two to four hours of analgesia suffices. EMLA cream combining lidocaine and prilocaine provides topical local anesthesia for surface procedures and catheter placement, though transdermal penetration limits its usefulness for procedures involving deeper structures. Each local anesthetic has a role in rabbit medicine, and veterinary teams should be familiar with the characteristics of available options to select appropriately for individual cases.

Systemic analgesics complement rather than replace local anesthetic techniques in comprehensive rabbit pain management protocols. Nonsteroidal anti-inflammatory drugs, particularly meloxicam, provide systemic analgesia addressing inflammation-related pain components that local anesthetics do not target. Opioids including buprenorphine offer additional pain control that extends beyond the duration of local anesthetic blocks. The combination of local anesthesia with systemic analgesics produces superior overall pain management compared to either approach alone.

Adjuvant medications may be combined with bupivacaine to enhance or prolong local anesthetic effects in some protocols. The addition of preservative-free opioids to epidural bupivacaine is well-established in various species, though specific rabbit protocols should be developed by experienced practitioners. Alpha-2 agonists such as dexmedetomidine may be combined with local anesthetics for regional blocks in some settings. These combinations require additional expertise and should be reserved for practitioners with specific training in their use.

Supportive care measures complement analgesic medications in promoting rabbit patient comfort and recovery. Maintaining normal gastrointestinal function through continued access to hay and water, appropriate environmental temperature, and reduction of stress all contribute to overall wellbeing. Prokinetic medications may be indicated when GI slowing develops, and subcutaneous fluids support hydration in patients with reduced oral intake. The comprehensive approach to rabbit perioperative care recognizes that pain management represents just one component of a multifaceted strategy for optimal patient outcomes.